Skip to main content

Table 1 Clinical, genetic and pathologic characteristics of participants

From: Variation in TMEM106B in chronic traumatic encephalopathy

 

Controls

(n = 376)

CTE cases

(n = 86)

P Value

Age (mean ± SD (range))

61.02 ± 10.2 (35–90)

57.02 ± 21.19 (17–89)

0.01

Years of exposure (mean ± SD (range))

–

13.49 ± 5.47 (1–31)

–

Cases with dementia (%)

–

33 (38.4%)

–

TMEM106B MAF

43.2%

41.9%

0.71

rs3173615 genotypes

  

0.74

 CC (%)

123 (32.7%)

29 (33.7%)

 

 CG (%)

181 (48.1%)

42 (48.8%)

 

 GG (%)

72 (19.1%)

15 (17.4%)

 

CERAD (mean ± SD)

–

0.29 ± 0.50

–

Cases with TDP-43 (%)

–

27 (31.4%)

–

AT8 Quartiles (positive pixel density/mm2 ± SD)

 

 1

–

283 ± 221

 

 2

–

2863 ± 1362

 

 3

–

10,438 ± 3715

 

 4

–

65,914 ± 62,629

 

CD68 Quartiles (Positive cell/mm2 ± SD)

 1

–

93 ± 15

 

 2

–

138 ± 10

 

 3

–

171 ± 10

 

 4

–

226 ± 31

 
  1. CERAD Consortium to establish a registry for Alzheimer’s disease, CTE Chronic Traumatic Encephalopathy (Ranges from Stage I-IV), MAF minor allele frequency